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Background: It has been suggested that gut microbiota is altered in Type 2 Diabetes
Mellitus (T2DM) patients.
Objective: This study was to evaluate the effect of the prebiotic xylooligosaccharide
(XOS) on the gut microbiota in both healthy and prediabetic (Pre-DM) subjects, as well
as impaired glucose tolerance (IGT) in Pre-DM.
Subjects/Methods: Pre-DM (n = 13) or healthy (n = 16) subjects were randomized
to receive 2 g/day XOS or placebo for 8-weeks. In Pre-DM subjects, body composition
and oral glucose tolerance test (OGTT) was done at baseline and week 8. Stool from
Pre-DM and healthy subjects at baseline and week 8 was analyzed for gut microbiota
characterization using Illumina MiSeq sequencing.
Results: We identified 40 Pre-DM associated bacterial taxa. Among them, the
abundance of the genera Enterorhabdus, Howardella, and Slackiawas higher in Pre-DM.
XOS significantly decreased or reversed the increase in abundance of Howardella,
Enterorhabdus, and Slackia observed in healthy or Pre-DM subjects. Abundance of the
species Blautia hydrogenotrophica was lower in pre-DM subjects, while XOS increased
its abundance. In Pre-DM, XOS showed a tendency to reduce OGTT 2-h insulin
levels (P = 0.13), but had no effect on body composition, HOMA-IR, serum glucose,
triglyceride, satiety hormones, and TNFα.
Conclusion: This is the first clinical observation of modifications of the gut microbiota by
XOS in both healthy and Pre-DM subjects in a pilot study. Prebiotic XOSmay be beneficial
in reversing changes in the gut microbiota during the development of diabetes.
Clinical trial registration: NCT01944904 (https://clinicaltrials.gov/ct2/show/
NCT01944904).
Keywords: xylooligosaccharide, prediabetic, diabetes, gut, microbiota
Abbreviations: XOS, xylooligosaccharide; Pre-DM, prediabetic; BMI, body mass index; T2DM, Type 2 Diabetes Mellitus;
FOS, fructooligosaccharides; GOS, galactooligosaccharides; OGTT, oral glucose tolerance test OGTT.
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Introduction
Increasing evidence indicates that changes in gut microbiota
composition might contribute to the development of metabolic
disorders such as obesity and T2DM (Qin et al., 2012).
Several mechanisms have been proposed regarding how gut
bacteria could facilitate the pathogenesis of T2DM (Shen
et al., 2013). Studies suggest that gut bacteria influence whole-
body metabolism through regulation of the host’s immune
response, energy extraction and utilization, intestinal glucose
absorption, and lipid metabolism (Musso et al., 2011). The
central feature of obesity and T2DM is insulin resistance,
potentially caused by low-grade inflammation resulting from
nutrient excess and leading to endoplasmic reticulum (ER)
stress. More and more research has shown that gut microbiota
is another important factor for this low-grade inflammation
(Chassaing and Gewirtz, 2014). The Bacteroidetes/Firmicutes
ratio is associated with increased plasma glucose concentrations
and a decrease in butyrate-producing bacteria in T2DM patients
(Larsen et al., 2010; Shen et al., 2013). Recent studies in mice have
demonstrated that an increase in the abundance of Bifidobacteria
and Akkermansia muciniphila attenuated high fat diet-induced
metabolic complications (Everard et al., 2013).
Pre-DM refers to the intermediate stage between
normoglycemia and overt diabetes mellitus. Pre-DM is
characterized by glucose dysregulation and a higher risk of
developing T2DM and other associated complications (Portero
McLellan et al., 2014). However, not all individuals with Pre-DM
progress to overt T2DM. With changes in lifestyle and diet,
the progression of Pre-DM to T2DM can be prevented or
delayed (Portero McLellan et al., 2014). Given the significant
involvement of certain gut bacteria in host metabolism (Shen
et al., 2013), therapeutic manipulation of the gut microbiota has
been proposed for both individuals with T2DM and in those at
risk of developing the condition.
Prebiotics are highly effective and important for many
applications in medicine. They are not digestible and do not
contribute to human nourishment, but rather exert a profound
effect on the human gut microbiota (International Scientific
Association for Probiotics and Prebiotics, 2004). Prebiotic-
induced modulation of gut microbiota has been developed
and widely used (Everard et al., 2011). The principal effect of
prebiotics on the human gut microbiota is to stimulate the
growth of the Bifidobacterium and Lactobacillus genera (Marotti
et al., 2012). Prebiotic treatment is known to modulate host gene
expression and metabolism as well (Everard et al., 2011). Dietary
intervention using prebiotic inulin or oligofructose (FOS) alters
the gut microflora composition by promoting the growth of
beneficial bacteria such as Bifidobacterium, Lactobacillus, and A.
muciniphila (Rossi et al., 2005; Choi and Shin, 2006). However,
the mechanisms associating prebiotics and its beneficial effects
have yet to be fully understood. Further studies are needed to
examine the precise physiological roles of prebiotics on human
bowel flora and in host immune function.
Xylooligosaccharide (XOS) is a recent prebiotic that can be
incorporated into many food products (Aachary and Prapulla,
2011). Our lab previously reported that XOS, at the dose of
2.8 g/day, was well tolerated, and modified the gut bacterial
composition in healthy people (Finegold et al., 2014). A
consideration of the gut microbiota in the context of health
benefits of XOS in Pre-DM is especially relevant since recent
research has indicated a critical role of gut microbiota in the
development of T2DM (Qin et al., 2012). The present study
was designed to determine the effect of XOS supplementation
on the gut microbiota in healthy and pre-DM individuals. Since
the ultimate objective of this research is to explore the potential
effects of XOS in the prevention of progression of Pre-DM to
T2DM, we also evaluated the effects of XOS in the management
of IGT, body composition, and inflammatory marker in Pre-DM
subjects.
Materials and Methods
Subjects
This was a double-blind, randomized, placebo-controlled study
with 34 subjects who were recruited based on inclusion and
exclusion criteria. The study population consisted of 16 healthy
subjects (placebo: n = 9; XOS: n = 7) and 13 Pre-DM subjects
(placebo: n = 6; XOS: n = 7).
Ethics
The study was carried out in accordance with the guidelines of
the Office for Protection of Research Subjects of the University
of California, Los Angeles and the Institutional Review Board of
the VA Greater LA Health Center. All subjects provided written
informed consent before the study began.
Study Design
The enrollment criteria for healthy participants was fasting
plasma glucose of 65–100 mg/dl, Participants in the Pre-DM
study were selected based on the American Diabetes Association
criteria for impaired fasting glucose (fasting plasma glucose of
100–125 mg/dl) and/or HgbA1c (5.7–6.4%) (American Diabetes
Association, 2014). Over the span of 8 weeks, both healthy
and Pre-DM subjects were randomly assigned to take daily a
capsule supplement containing either 2 g XOS (2.8 grams of
70% XOS) or placebo. The XOS and placebo were provided
by Life Bridge International (Riverside, CA). The XOS was
manufactured by Shandong Longlive Bio-Technology Co., Ltd.,
China. The placebo capsules contained maltodextrin. The study
consisted of three phases: a 2-week run-in phase, and an 8-week
intervention phase.
Stool Collection
A total of two stools were collected from each subject: at baseline
and week 8 of the intervention periods. Each time the entire stool
specimen was obtained. The specimen was placed in a large, zip-
lock freezer bag and all air was pushed out of the bag as the zip
lock was closed. The specimen was delivered on ice to the UCLA
Center for Human Nutrition within 24 h of collection where it
was immediately stored at−20◦C.
Miseq Sequencing
DNA from stool was extracted using a commercial extraction
system (QIAamp Stool DNA Extraction Kit, Qiagen, Valencia,
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CA). The quality of the DNA samples was confirmed using
a Bio-Rad Experion system (Bio-Rad Laboratories, CA, USA).
The 16S rRNA gene V4 variable region PCR primers 515/806
with barcode on the forward primer were used in a 30 cycle
PCR using the HotStarTaq Plus Master Mix Kit (Qiagen, USA)
under the following conditions: 94◦C for 3min, followed by
28 cycles of 94◦C for 30 s, 53◦C for 40 s and 72◦C for 1min,
after which a final elongation step at 72◦C for 5min was
performed. After amplification, PCR products are checked in
2% agarose gel to determine the success of amplification and
the relative intensity of bands. Sequencing was performed at
MR DNA (www.mrdnalab.com, Shallowater, TX, USA) on a
MiSeq following the manufacturer’s guidelines. Sequence data
were processed using a proprietary analysis pipeline (MR DNA,
Shallowater, TX, USA). Operational taxonomic units (OTUs)
were defined by clustering at 3% divergence (97% similarity).
Final OTUs were taxonomically classified using BLASTn against
a curated GreenGenes database (DeSantis et al., 2006).
Body Composition
Body composition was measured using the Tanita-BC418
bioelectrical impedance analyzer (Tanita Corp., Japan).
Glucose Tolerance Test
On the test days at baseline and week 8, Pre-DM subjects
remained in a fasting state for 2.5 h prior to the beginning of
OGTT. The 75 g glucose cola was administrated immediately
after the basal blood draw at 0min. Subsequent blood samples
were taken 30, 60, and 120min afterwards. Serum samples were
kept at −80◦C. The insulin resistance index assessed by the
homeostasis model (HOMA-IR) was calculated as follows (Allard
et al., 2003): (fasting blood glucose [mmol/l] × fasting plasma
insulin [µU/ml])/22.5.
Blood Biochemical Analysis
Blood samples were collected and coded to protect patient
confidentiality. Lipids, insulin, glucose, and satiety hormones
were measured. Serum triglycerides were determined using
a enzymatic method (Pointe Scientific, MI). Serum glucose
was determined using Glucose Assay kit (Cayman Chemical
Company, MI). Serum insulin, active GLP-1, leptin, pancreatic
polypeptides (PP) and TNFα were determined using the
MILLIPLEX map kit (EMD Millipore, Billerica, MA) and data
were captured and processed using Luminext 200 with xPonent
software.
Statistics
Demographic data at baseline were analyzed and presented as
mean ± SD and two sample t-tests were used for comparisons
between the placebo and XOS groups. For analysis of serum
variables, such as insulin, glucose, values of mean± SE at baseline
and week 8 were presented for all groups, and two sample t-test
was used to compare the two groups at baseline and 8 weeks. For
DNA sequencing analyses, Wilcoxon rank sum test was utilized
to evaluate the differences between study groups. All tests are two
sided and all analyses were conducted using SAS 9.3 (Statistical
Analysis System, Cary, NC, 2008) and R (www.r-project.org)
software.
Results
Subjects
The study population consisted of 16 healthy participants (4
men and 12 women) aged between 21 and 49 years, and 13
Pre-DM participants (9 men and 4 women) aged between
30 and 63. Participants did not report any adverse effects or
symptoms with the XOS intervention at 2 g/day. Table 1 shows
the baseline characteristics of the participants in the four groups.
The composition of the fecal microbiome from all healthy
participants and Pre-DM participants was analyzed by Miseq
sequencing.
Gut Microbial Composition Changes Related to
Pre-DM
Miseq sequencing was used to compare the gut microbial
composition of baseline samples from 16 healthy and
13 Pre-DM subjects. The abundance (percentage of total
sequences) of 1 phylum, 1 class, 3 families, 13 genera, and
22 species, was significantly different between healthy and
Pre-DM (Supplementary Table 1). Composition of phyla
in healthy and Pre-DM groups is displayed in Figure 1A.
The abundance of infectious and T2DM related phylum
Synergistetes (Baumgartner et al., 2012; Qin et al., 2012)
was significantly higher in Pre-DM compared with healthy
subjects (P ≤ 0.05) (Figure 1A). In addition, 13 genera
responded significantly in Pre-DM (P ≤ 0.05) (Figure 1B).
The abundances of Allisonella, Cloacibacillus, Enterorhabdus,
Howardella, Megamonas, and Slackia were significantly
higher, while Adlercreutzia, Anaerococcus, Ethanoligenens,
Gordonibacter, Lactococcus, Parasutterella, and Tissierella were
greatly reduced in Pre-DM compared with healthy subjects
(Figure 1B).
TABLE 1 | Baseline characteristics of the study participants.
Healthy placebo (n = 9) Healthy XOS (n = 7) Pre-DM placebo (n = 6) Pre-DM XOS (n = 7)
Age, year 31.9 ± 6.9 31.7 ± 9.3 44.8 ± 11.2 55.0 ± 6.2
Weight, kg 65.4 ± 14.0 69.9 ± 13.0 94.9 ± 15.9 97.4 ± 22.7
BMI, kg/m2 23.4 ± 3.2 25.6 ± 3.2 33.6 ± 7.2 32.2 ± 4.2
Values are presented as mean ± standard deviation (SD). For all characteristics, there were no significant differences between the placebo and XOS groups (all P > 0.05, based on
independent sample t-tests). BMI, body mass index.
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FIGURE 1 | Comparison of gut microbiota composition between
healthy (n = 16) and Pre-DM (n = 13) subjects. (A) Pie charts depict
mean abundance (% of total) of the indicated phyla. (B) Bar graph of
genera shows significant differences in abundance between healthy and
Pre-DM subjects. Values are presented as mean ± standard error (SE)
*P ≤ 0.05.
Effects of XOS Supplementation on the Gut
Microbiota in Healthy and Pre-DM Subjects
The overall changes of bacterial composition with 8-week XOS
intervention were assessed at the phylum and genus levels
(Figures 2, 3). Significant XOS-induced changes were found
for 1 phyla, 3 classes, 7 families, 23 genera, and 25 species
in healthy subjects (Figure 2 and Supplementary Table 2),
and 3 classes, 1 families, 7 genera, and 17 species in Pre-
DM subjects (Figure 3 and Supplementary Table 3). The mean
abundance of indicated phyla of healthy subjects in placebo
and XOS groups at baseline and week 8 are displayed in
Figure 2A. The phylum Firmicutes showed a 20% increase
in abundance over 8 weeks in placebo groups of healthy
subjects, while XOS intervention significantly reversed this
increase (P ≤ 0.05) (Figure 2A). The mean abundance of
Verrucomicrobia increased in XOS groups of healthy subjects
as well. Among genera with an average abundance >1%
in at least one group, six were significantly regulated by
XOS. An increase of infectious disease related Streptococcus
and Subdoligranulum in placebo groups was largely inhibited
by XOS in healthy subjects (Figure 2B). The 8-week XOS
intervention did not induce significant changes of gut microbiota
at the phylum level in Pre-DM subjects (Figure 3A). At the
genus level, Blautia, Anaerotruncus, Dialister, and Oscillospira
were four abundant genera identified with significant XOS-
induced changes in Pre-DM subjects. XOS diminished or
reversed the magnitude of population decline in all four genera
(Figure 3B).
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FIGURE 2 | Effects of XOS supplementation on gut microbiota in
healthy subjects (n = 16). (A) Pie charts display the mean abundance of
indicated phyla of healthy subjects receiving placebo (n = 9) and XOS (n = 7)
at baseline and week 8. (B) Bar graph of genera shows significant difference
in abundance between placebo and XOS groups. Values are presented as
mean ± standard error (SE) *P ≤ 0.05.
XOS Supplementation Reversed Gut Bacterial
Alterations Associated with Pre-DM
Of the 40 Pre-DM associated bacterial taxa (Supplementary Table
1) identified in this study, the abundances of the Enterorhabdus,
Howardella, and Slackia genera were elevated in Pre-DM. The
8-week XOS intervention significantly diminished or reversed
the abundance increase of Howardella and Slackia observed in
the placebo group of healthy subjects, as well as Enterorhabdus
in Pre-DM subjects (Figures 4A–C). B. hydrogenotrophica was
less abundant in Pre-DM subjects (Supplementary Table 1),
but XOS intervention significantly reversed the decrease in B.
hydrogenotrophica abundance observed in the placebo group of
Pre-DM subjects (P ≤ 0.05) (Figure 4D).
Effects of XOS on Body Composition, Metabolic,
and Immunological Markers in Pre-DM Subjects
In Pre-DM subjects, body composition, blood tests, and oral
glucose tolerance tests (OGTT) were done at baseline and after
8 weeks of XOS intervention. Body weight and indexes of
overall adiposity such as BMI, % fat, and % trunk fat were
not changed by 8-week XOS intervention (Figure 5). Despite
significant inter-individual variations in insulin responses
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FIGURE 3 | Effects of XOS supplementation on gut microbiota in
Pre-DM subjects (n = 13). (A) Pie charts display the mean abundance of
indicated phyla of Pre-DM subjects receiving placebo (n = 6) and XOS
(n = 7) at baseline and week 8. (B) Bar graph of genera shows significant
difference in abundance between placebo and XOS groups. Values are
presented as mean ± standard error (SE) *P ≤ 0.05.
among Pre-DM subjects, OGTT 2-h insulin response showed
a tendency to decrease with XOS intervention in Pre-DM
(P = 0.13) (Figure 6A). No significant XOS-related differences
were observed in serum glucose, HOMA-IR, active GLP-1,
triglycerides, leptin, PP, or the inflammatory marker TNFα
(Figures 6B–H).
Discussion
Emerging evidence suggests that metabolic disorders including
T2DM are associated with a pro-inflammatory state secondary
to dysbiosis of gut bacterial flora (Larsen et al., 2010; Esteve
et al., 2011; Musso et al., 2011). In addition, literature has
documented the translocation of gut bacteria to blood and tissues
in T2DM, and probiotic Bifidobacterium treatment prevents
bacterial translocation and protects against T2DM (Cani et al.,
2007; Amar et al., 2011). Together, these findings suggest that gut
bacteria are an important modifier of T2DM.
The effects of oligosaccharides including XOS, FOS, and
galactooligosaccharides (GOS) in the treatment of T2DM have
gained interest. However, studies have shown inconsistent
results. In T2DM patients, Yamashita et al. demonstrated that
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FIGURE 4 | XOS selectively regulated some of the Pre-DM
associated bacterial taxa in healthy subjects (n = 16) or Pre-DM
subjects (n = 13) during 8 weeks. The abundances of Pre-DM
associated Howardella (A), Slackia (B), and Enterorhabdus (C) were
greatly reduced by XOS in healthy and Pre-DM subjects, respectively. (D)
The abundance of healthy associated Blautia hydrogenotrophica was
enhanced by XOS in healthy and Pre-DM subjects. Values are presented
as mean ± standard error (SE) *P ≤ 0.05.
FIGURE 5 | Body weight (A), BMI (B), % Fat (C), and % Trunk fat (D) in Pre-DM subjects at baseline and after 8 weeks placebo (n = 6) or XOS (n = 7)
treatment. Data are means ± standard errors (SE).
FOS at a dose of 8 g per day for 14 days resulted in a reduction of
serum glucose, while Alles et al. showed that daily consumption
of FOS at 15 g for 20 days had no effect on serum glucose
level (Yamashita et al., 1984; Alles et al., 1999). Chan et al.
showed that 4 g per day of XOS for 8 weeks was effective in
reducing blood glucose and lipids in Taiwan T2DM patients
(Sheu et al., 2008), and for 21 days benefited intestinal health
and increased of Bifidobacteria in elderly subjects (Chung et al.,
2007). Another study reported that both XOS and FOS dietary
intervention reduced hyperglycaemia in diabetic rats (Gobinath
et al., 2010). In addition, we found that 2 g per day of XOS
for 8 weeks increased the Bifidobacteria abundance in healthy
Americans without any gastrointestinal side effects (Finegold
et al., 2014). Overall, a significant number of studies have shown
oligosaccharides to be an effective option for lowering blood
sugar in T2DM as well as improving intestinal health.
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FIGURE 6 | Mean of parameters with SE at baseline and 8 weeks
were compared between placebo- (n = 6) and XOS-treated (n = 7)
group in Pre-DM subjects during the 120-min OGTT test. (A) Serum
Insulin. (B) Serum glucose. (C) HOMA-IR. (D) Serum active GLP-1. (E)
Serum triglyceride. (F) Serum pancreatic polypeptides. (G) Serum leptin. (H)
Serum TNF α. Values are presented as mean ± standard error (SE).
In the present study, both healthy and Pre-DM subjects were
given 2 g per day of XOS for 8 weeks. Miseq sequencing was
used to evaluate the potential of XOS in preventing the dysbiosis
of gut microbiota during the development of T2DM. We found
that XOS had a clear impact on gut microbiota in both healthy
and Pre-DM groups, and resulted in dramatic shifts of several
bacterial taxa associated with Pre-DM. Among them, Dialister
spp. and Slackia are pro-inflammatory (Rocas and Siqueira,
2006; Kim et al., 2010), and were greatly reduced by XOS.
Additionally, T2DM associated lactic acid bacteria Enterococcus,
Streptococcus, and Lactobacillus (Remely et al., 2013) were also
greatly reduced by XOS. The inhibitory effect of XOS on other
opportunistic pathogens, such as Clostridia, Streptococcaceae,
and Subdoligranulum, further supports that XOS can potentially
promote an optimal gut microbiota profile, and consequently
reduce the risk of T2DM.
Miseq sequencing data also revealed that gut microbial
composition of healthy subjects at different taxonomic levels
was different from Pre-DM subjects. Some of our findings
are consistent with previous T2DM studies of gut microflora
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(Qin et al., 2012; Zhang et al., 2013; Finegold et al., 2014),
substantiating the significant association of these changes with
the progression of T2DM (Supplementary Table 1). Studies
showed that the Megamonas OTU was most enriched in Pre-
DM, compared to healthy or T2DM individuals (Qin et al., 2012;
Zhang et al., 2013). The abundance of Megamonas in our study
was 200-fold higher in Pre-DM than healthy subjects. We also
found that the abundance of the phylum Synergistetes in Pre-
DM was about 50 fold higher compared with healthy subjects.
The Synergistetes appear to be more numerous in individuals
with oral-related diseases as well as gut and soft tissue infections
(Vartoukian et al., 2007). Another two infectious or metabolic
disease related bacteria Eubacteriaceae (Plieskatt et al., 2013)
and Slackia (Kim et al., 2010), were more abundant in Pre-
DM individuals. The Pre-DM associated enrichment of infectious
bacteria and the appearance of oral bacteria in the gut suggest
that the host immune system may lose control over these
opportunistic pathogens during the development of T2DM.
Both animal and clinical studies have shown that XOS
supplementation greatly increases the Bifidobacterium
population (Campbell et al., 1997; Chung et al., 2007; Finegold
et al., 2014). We previously showed that an increase of
Bifidobacterium abundance was detectable only with an in vitro
culture method, and not pyrosequencing (Finegold et al.,
2014). Using Miseq sequencing alone, the abundances of the
Bifidobacterium genus, as well as the Bifidobacterium longum,
Bifidobacterium bifidum, and Bifidobacterium adolescentis
species were not significantly increased by XOS in healthy
subjects (Supplementary Table 4). However, we found that XOS
largely inhibited bacterial taxa related to infectious andmetabolic
disease, such as family Streptococcaceae, class Clostridia, and
genera Subdoligranulum, Gordonibacter, and Streptococcus in
healthy subjects (Supplementary Table 1). Furthermore, in
healthy subjects, XOS greatly reduced the abundance of bacteria
related to obesity or T2DM, including phylum Firmicutes and
genera Subdoligranulum and Bacilli (Remely et al., 2013; Zhang
et al., 2013). In Pre-DM subjects, XOS diminished or reversed
the magnitude of population decline in about 70% bacterial
taxa identified with a significant change from its baseline levels
between treatment groups (Supplementary Table 2). The family
Veillonellaceae and genera Oscillospira and Dialister exhibited
population declines in the placebo group, but demonstrated
large increases in abundance in the XOS group. Abnormally
low levels of Veillonellaceae and Dialister have been described
in autistic children (Kang et al., 2013) and patients of Crohn’s
disease (Joossens et al., 2011). Dietary whole grain intervention
(Martinez et al., 2013) and corn fiber (Hooda et al., 2012)
increased the Dialister and Veillonellaceae abundance. The genus
Oscillospira has been associated with lean BMI (Tims et al.,
2013). The inhibition of Firmicutes and increase of Oscillospira
abundance suggest a potential role of XOS in weight control.
To the best of our knowledge, this is the first clinical
study evaluating the effects of daily treatment with 2 g of
XOS on glucose tolerance and insulin resistance in Pre-DM
adults. In our experience, a dose of 2 g does not cause any
gastrointestinal side effects (Finegold et al., 2014). Eight weeks
of XOS supplementation tended to increase insulin sensitivity
by lowering OGTT 2-h insulin response (P = 0.11), while no
significant improvement of Pre-DM subjects’ metabolic situation
was observed, using the parameters of body composition, serum
glucose, triglyceride, satiety hormones and inflammation marker
TNFα. The TNFα levels (4.91 ± 1.85 pg/ml) of Pre-DM subjects
in our study are normal, slightly lower than the reported TNFα
(∼15–20 pg/ml) of eastern Indian Pre-DM population (Dutta
et al., 2013) and much lower than T2DM (range from 87
to 112 pg/ml) (Goyal et al., 2012). Since we enrolled pre-DM
subjects with impaired glucose tolerance (IGT) and without any
other medical conditions we possibly did not observe elevated
TNFα level. Pre-DM is a dynamic intermediate stage in the
progression to T2DM, therefore it is very likely, subjects that
met the selection criteria for Pre-DM are at different stages even
though they are all classified as Pre-DM. Besides, studies also
suggest a connection between TNFα gene polymorphism, its
blood levels and the tendency to progression from Pre-DM to
T2DM (Dutta et al., 2013). Therefore, more studies are needed to
improve our understanding of the relationship between TNAα,
Pre-DM staging, and T2DM progression. Our results do not
agree with Chan et al. study in T2DM. However, this discrepancy
could be explained by difference in XOS dose, study population
and disease stages. It is possible that 2 g per day of XOS may
have been too low to induce a difference in glucose tolerance.
However, we observed a trend of increased insulin sensitivity
by lowering OGTT 2-h insulin response at this dosage. Pre-DM
is a strong risk factor for the development of T2DM, and the
regulation of glucose metabolism and insulin sensitivity could be
really dynamic during this stage. We think future clinical study
with large sample size will be needed to confirm the benefits of
XOS in Pre-DM.
In conclusion, XOS significantly modified gut microbiota in
both healthy and Pre-DM subjects, and resulted in dramatic shifts
of 4 bacterial taxa associated with Pre-DM. Future studies with
larger sample size are needed to study the metabolic impact of
XOS and understand the connection between XOS-mediated gut
microbiota changes and the pathogenesis of T2DM.
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